Literature DB >> 14505209

The roles of transforming growth factor type beta3 (TGF-beta3) and mast cells in the pathogenesis of scleroderma.

M Kemal Ozbilgin1, Sevinc Inan.   

Abstract

Scleroderma is a connective tissue disorder characterised by excessive accumulation of collagen in the skin and internal organs. The most likely explanation for this process is local activation of collagen synthesis from fibroblasts. Our intention was to elucidate whether TGF-beta3 and mast cells play a pathogenic role in abnormal connective tissue formation in scleroderma. In this study, skin biopsies from 20 patients with scleroderma and five from healthy individuals were studied by an indirect immunoperoxidase technique to determine the immunoreactivity of TGF-beta3 in the dermis. In addition, skin samples were stained with toluidine blue to count the number of mast cells in scleroderma, and tissues were examined under the electron microscope to evaluate the ultrastructural changes. Increased TGF-beta3 immunoreactivities were detected in the dermis in the patient's skin, suggesting the presence of a subpopulation responsible for the increased collagen production. Mast cell counts in the skin of patients with scleroderma were significantly greater (19.2 +/- 4.1/unit) than those of normal controls (4.4 +/- 1.2/unit). Ultrastructural observations indicated that there is a close relationship between the mast cells and fibroblasts. These results suggest that fibrosis in scleroderma could evolve through the activation of fibroblasts and the regulatory mechanisms that appear to modulate the behavior of these cells with respect to collagen production.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14505209     DOI: 10.1007/s10067-003-0706-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  13 in total

Review 1.  Neuroinflammatory Mechanisms of Connective Tissue Fibrosis: Targeting Neurogenic and Mast Cell Contributions.

Authors:  Michael J Monument; David A Hart; Paul T Salo; A Dean Befus; Kevin A Hildebrand
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-03-01       Impact factor: 4.730

2.  Nanoparticle delivery of RNA-based therapeutics to alter the vocal fold tissue response to injury.

Authors:  Nao Hiwatashi; Iv Kraja; Peter A Benedict; Gregory R Dion; Renjie Bing; Bernard Rousseau; Milan R Amin; Danielle M Nalband; Kent Kirshenbaum; Ryan C Branski
Journal:  Laryngoscope       Date:  2017-12-14       Impact factor: 3.325

3.  The role of Smad3 in the fibrotic phenotype in human vocal fold fibroblasts.

Authors:  Ryan C Branski; Renjie Bing; Iv Kraja; Milan R Amin
Journal:  Laryngoscope       Date:  2015-09-30       Impact factor: 3.325

Review 4.  Transforming growth factor β--at the centre of systemic sclerosis.

Authors:  Robert Lafyatis
Journal:  Nat Rev Rheumatol       Date:  2014-08-19       Impact factor: 20.543

5.  SMAD3 expression and regulation of fibroplasia in vocal fold injury.

Authors:  Nao Hiwatashi; Peter A Benedict; Gregory R Dion; Renjie Bing; Iv Kraja; Milan R Amin; Ryan C Branski
Journal:  Laryngoscope       Date:  2017-05-20       Impact factor: 3.325

6.  Homeostatic role of transforming growth factor-beta in the oral cavity and esophagus of mice and its expression by mast cells in these tissues.

Authors:  Allison Vitsky; James Waire; Robert Pawliuk; Arden Bond; Douglas Matthews; Emily Lacasse; Michael L Hawes; Carol Nelson; Susan Richards; Peter A Piepenhagen; Richard D Garman; Laura Andrews; Beth L Thurberg; Scott Lonning; Steve Ledbetter; Melanie C Ruzek
Journal:  Am J Pathol       Date:  2009-04-30       Impact factor: 4.307

7.  Generalized morphea after breast cancer radiation therapy.

Authors:  Jonathan Kushi; M E Csuka
Journal:  Case Rep Rheumatol       Date:  2011-11-03

8.  Activated MCTC mast cells infiltrate diseased lung areas in cystic fibrosis and idiopathic pulmonary fibrosis.

Authors:  Cecilia K Andersson; Annika Andersson-Sjöland; Michiko Mori; Oskar Hallgren; Annie Pardo; Leif Eriksson; Leif Bjermer; Claes-Göran Löfdahl; Moises Selman; Gunilla Westergren-Thorsson; Jonas S Erjefält
Journal:  Respir Res       Date:  2011-10-20

Review 9.  New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.

Authors:  Alain Lescoat; John Varga; Marco Matucci-Cerinic; Dinesh Khanna
Journal:  Expert Opin Investig Drugs       Date:  2021-05-13       Impact factor: 6.498

10.  Mast cell regulation of the immune response.

Authors:  John J Ryan; Johanna K Morales; Yves T Falanga; Josephine F A Fernando; Matthew R Macey
Journal:  World Allergy Organ J       Date:  2009-10       Impact factor: 4.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.